Findell Capital Management LLC Acquires 298,380 Shares of Establishment Labs Holdings Inc. (NASDAQ:ESTA)

Findell Capital Management LLC boosted its position in shares of Establishment Labs Holdings Inc. (NASDAQ:ESTA) by 28.5% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 1,346,480 shares of the company’s stock after purchasing an additional 298,380 shares during the period. Establishment Labs accounts for 25.4% of Findell Capital Management LLC’s investment portfolio, making the stock its biggest holding. Findell Capital Management LLC owned 4.81% of Establishment Labs worth $62,032,000 at the end of the most recent reporting period.

Other institutional investors have also recently bought and sold shares of the company. Brown Advisory Inc. increased its stake in Establishment Labs by 23.1% in the 4th quarter. Brown Advisory Inc. now owns 2,338,369 shares of the company’s stock valued at $107,729,000 after buying an additional 438,057 shares during the last quarter. Capital Research Global Investors increased its position in Establishment Labs by 29.3% during the 4th quarter. Capital Research Global Investors now owns 1,911,525 shares of the company’s stock valued at $88,064,000 after purchasing an additional 433,484 shares during the period. William Blair Investment Management LLC boosted its position in shares of Establishment Labs by 44.1% during the 4th quarter. William Blair Investment Management LLC now owns 812,825 shares of the company’s stock worth $37,447,000 after purchasing an additional 248,888 shares in the last quarter. Bamco Inc. NY lifted its holdings in shares of Establishment Labs by 53.8% in the fourth quarter. Bamco Inc. NY now owns 752,886 shares of the company’s stock valued at $34,685,000 after purchasing an additional 263,500 shares in the last quarter. Finally, Balyasny Asset Management L.P. boosted its holdings in shares of Establishment Labs by 16.3% in the 4th quarter. Balyasny Asset Management L.P. now owns 558,289 shares of the company’s stock worth $25,720,000 after buying an additional 78,123 shares during the last quarter. Institutional investors and hedge funds own 72.91% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have commented on ESTA. Stephens reissued an “overweight” rating and issued a $52.00 price target on shares of Establishment Labs in a research note on Thursday, March 6th. Needham & Company LLC started coverage on Establishment Labs in a report on Monday, April 14th. They issued a “hold” rating on the stock. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $57.40.

Establishment Labs Price Performance

Shares of NASDAQ:ESTA opened at $34.81 on Friday. Establishment Labs Holdings Inc. has a 52 week low of $26.56 and a 52 week high of $60.12. The company has a market cap of $1.00 billion, a P/E ratio of -13.49 and a beta of 0.73. The company has a 50-day moving average price of $35.08 and a 200 day moving average price of $38.65. The company has a quick ratio of 2.29, a current ratio of 3.62 and a debt-to-equity ratio of 5.94.

Establishment Labs (NASDAQ:ESTA) last posted its quarterly earnings data on Wednesday, May 7th. The company reported ($0.70) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.83) by $0.13. The company had revenue of $41.38 million for the quarter, compared to the consensus estimate of $41.15 million. Establishment Labs had a negative return on equity of 184.55% and a negative net margin of 46.13%. Establishment Labs’s revenue for the quarter was up 11.3% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.58) EPS. Research analysts predict that Establishment Labs Holdings Inc. will post -2.41 earnings per share for the current year.

About Establishment Labs

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.